Mechanisms of delayed elimination and decreased plasma protein binding of anticancer drugs which are mainly eliminated via the liver in cancer patients with severe renal failure
Mechanisms of delayed elimination and decreased plasma protein binding of anticancer drugs which are mainly eliminated via the liver in cancer patients with severe renal failure
批准号:
26460205
负责人:
Fujita Ken-ichi
金额:
$3.16万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2014
资助国家:
日本
项目状态:
已结题
起止时间:
2014-04-01 至 2017-03-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
期刊论文(17)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Inhibition of human hepatic transporter OATP1B1 by indole metabolites
吲哚代谢物对人肝转运蛋白 OATP1B1 的抑制
DOI:
--
发表时间:
2016
期刊:
影响因子:
--
作者:
[Natsumi Seba, Yusuke Masuo, Ken-ichi Fujita, Noritaka Nakamichi, Yasutsuna Sasaki, Yukio Kato]
通讯作者:
Yukio Kato
極めて腎機能が低下したがん患者において,SN-38の血漿蛋白結合は低下し遊離形濃度が顕著に上昇する.
在肾功能严重受损的癌症患者中,SN-38 的血浆蛋白结合减少,游离形式浓度显着增加。
DOI:
--
发表时间:
2015
期刊:
影响因子:
--
作者:
[Ken-ichi Fujita, Yusuke Masuo, Hidenori Okumura, Yasutsuna Sasaki and Yukio Kato, 藤田健一,増尾友祐,奥村英典,砂川優,嶋田顕,河原香織,秋山祐子,佐々木康綱,加藤将夫]
通讯作者:
藤田健一,増尾友祐,奥村英典,砂川優,嶋田顕,河原香織,秋山祐子,佐々木康綱,加藤将夫
Unfit症例におけるがん薬物療法の至適化と臨床薬理学:腎障害患者におけるイリノテカンの特異な体内動態と投与法(シンポジウム)
不适合病例的癌症药物治疗和临床药理学的优化:肾功能不全患者中伊立替康独特的药代动力学和给药方法(研讨会)
DOI:
--
发表时间:
2016
期刊:
影响因子:
--
作者:
[Ken-ichi Fujita, Yusuke Masuo, Hidenori Okumura, Yusuke Watanabe, Hiromichi Suzuki, Yu Sunakawa, Ken Shimada, Kaori Kawara, Yuko Akiyama, Masanori Kitamura, Munetaka Kunishima, Yasutsuna Sasaki, Yukio Kato, 藤田健一, 藤田健一]
通讯作者:
藤田健一
Delayed elimination of SN-38 in cancer patients with severe renal failure: mechanism and appropriate irinotecan dose (Symposium)
患有严重肾功能衰竭的癌症患者延迟消除 SN-38:机制和适当的伊立替康剂量(研讨会)
DOI:
--
发表时间:
2016
期刊:
影响因子:
--
作者:
[Natsumi Seba, Yusuke Masuo, Ken-ichi Fujita, Noritaka Nakamichi, Yasutsuna Sasaki, Yukio Kato, Ken-ichi Fujita]
通讯作者:
Ken-ichi Fujita
Delayed elimination of SN-38 in cancer patients with severe renal failure: mechanism and appropriate irinotecan dose
患有严重肾功能衰竭的癌症患者延迟消除 SN-38:机制和伊立替康适当剂量
DOI:
--
发表时间:
2016
期刊:
影响因子:
--
作者:
[Natsumi Seba, Yusuke Masuo, Ken-ichi Fujita, Noritaka Nakamichi, Yasutsuna Sasaki, Yukio Kato, Ken-ichi Fujita, Ken-ichi Fujita]
通讯作者:
Ken-ichi Fujita
共 17 条
Clinical impact of unbound-base pharmacokinetics of active metabolites of a tyrosine kinase inhibitor regorafenib
-
批准号:19K07204
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.83万
-
财政年份:2019
-
负责人:Fujita Ken-ichi
-
依托单位:
Development of catalytic reactions towards a realization of a hydrogen society
-
批准号:19H02715
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.15万
-
财政年份:2019
-
负责人:Fujita Ken-ichi
-
依托单位:
Regulation of drug efflux pump's activities and gene expression by drug-induced oxidative stress
-
批准号:16K08299
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.08万
-
财政年份:2016
-
负责人:Fujita Ken-ichi
-
依托单位:
Enhancement of magnetically recoverable transition metal catalysts by the introduction of hydrophobic field
-
批准号:26410200
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.33万
-
财政年份:2014
-
负责人:Fujita Ken-ichi
-
依托单位: